| |NOVEMBER 20249AI DIALYSIS MACHINE TO TRANSFORM RENAL CARE, CUTTING COSTS BY 75 PERCENTLYELL IMMUNOPHARMA ACQUIRES IMMPACT BIO TO EXPAND CAR T-CELL PIPELINEThe AI-powered smart haemodialysis machine aims to increase access to renal care and reduce costs by up to 75 Percent, bringing the price down to approximately Rs 2 lakh. Nephro Care India Limited (NCIL) is working with the National Institute of Technology in Silchar to create a prototype of an AI-enabled Smart Haemodialysis Machine that can be monitored remotely."The company, in collaboration with National Institute of Technology, Silchar, is developing the prototype with a grant from the Department of Science and Technology and Biotechnology, West Bengal and it is expected to be ready over the next 7-8 months," Dr Pratim Sengupta, Founder and MD & CEO of Nephro Care said.He stated that once the local machine is created, it will lower the cost from the current Rs 7.5-8 lakh to Rs 2 lakh, a reduction of 70-75 per cent. Saying that most haemodialysis machines in India are currently imported, Sengupta pointed out that device manufacturing locally could lower costs, thus making treatment more affordable for patients with advanced renal failure and supporting the make in India initiative.The prototype will allow for remote monitoring of dialysis machines, increasing accessibility of treatment in rural and semi-urban areas and closing the gap. According to government calculations, approximately 220,000 individuals in India are diagnosed with end-stage renal disease (ESRD) each year, resulting in a need for an extra 34 million dialysis sessions annually. POLyell Immunopharma, Inc, located in South San Francisco, revealed that it has finalized a deal to purchase ImmPACT Bio USA Inc, a clinical-stage biotech company, as part of its efforts to develop advanced CAR T-cell therapies for cancer patients.IMPT-314, ImmPACT's main initiative, is a chimeric antigen receptor (CAR) T-cell product aimed at CD19/20, which Lyell plans to further progress for hematologic malignancies such as large B-cell lymphoma. IMPT-314 was created with the goal of surpassing the effectiveness of authorized CD19 CAR T-cell treatments by utilizing a dual-targeting CAR T-cell approach and enhancing CAR T-cell longevity by focusing on naïve and central memory T cells in the production process."Lyell's vision is to bring meaningful and durable clinical benefit to patients suffering from cancer with our next-generation cell therapies," stated Lynn Seely, Lyell's president and CEO. "The emerging data from ImmPACT's ongoing phase 1-2 trial and the phase 1 clinical data from a published UCLA-sponsored trial suggest the potential of IMPT-314 to have improved complete response rates and duration of response compared to the approved CD19 CAR T-cell therapies in CAR-naïve patients with aggressive B-cell lymphoma. Since licensing this product candidate from UCLA, the team at ImmPACT has made impressive progress in the multi-center IMPT-314 phase 1-2 clinical programme. We look forward to presenting initial data from this program at a major medical conference later this year and initiating a pivotal trial for IMPT-314 in 2025". PO
< Page 8 | Page 10 >